BioMerieux SA (BMXMF)
106.20
0.00 (0.00%)
USD |
OTCM |
May 07, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 12.55B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 1.79% |
| Valuation | |
| PE Ratio | 32.58 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.169 |
| Price to Book Value | 3.026 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.9232 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0987 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 52.87% |
Profile
| BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France. |
| URL | http://www.biomerieux.com |
| Investor Relations URL | https://www.biomerieux.com/en/finance |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Sep. 05, 2024 |
| Last Earnings Release | Mar. 14, 2024 |
| Next Ex-Dividend Date | Jun. 07, 2024 |
| Last Ex-Dividend Date | Jun. 06, 2023 |
Ratings
Profile
| BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France. |
| URL | http://www.biomerieux.com |
| Investor Relations URL | https://www.biomerieux.com/en/finance |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Sep. 05, 2024 |
| Last Earnings Release | Mar. 14, 2024 |
| Next Ex-Dividend Date | Jun. 07, 2024 |
| Last Ex-Dividend Date | Jun. 06, 2023 |